STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
26.63
+1.38 (5.47%)
At close: Nov 6, 2025, 4:00 PM EST
26.29
-0.34 (-1.28%)
After-hours: Nov 6, 2025, 7:49 PM EST
STAAR Surgical Company Revenue
STAAR Surgical Company had revenue of $94.73M in the quarter ending September 26, 2025, with 6.93% growth. This brings the company's revenue in the last twelve months to $230.59M, down -32.42% year-over-year. In the year 2024, STAAR Surgical Company had annual revenue of $313.90M, down -2.64%.
Revenue (ttm)
$230.59M
Revenue Growth
-32.42%
P/S Ratio
5.71
Revenue / Employee
$199,301
Employees
1,157
Market Cap
1.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 27, 2024 | 313.90M | -8.51M | -2.64% |
| Dec 29, 2023 | 322.42M | 38.02M | 13.37% |
| Dec 30, 2022 | 284.39M | 53.92M | 23.40% |
| Dec 31, 2021 | 230.47M | 67.01M | 41.00% |
| Jan 1, 2021 | 163.46M | 13.28M | 8.84% |
| Jan 3, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
STAA News
- 20 hours ago - Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated - Business Wire
- 1 day ago - STAAR Surgical Reports Third Quarter 2025 Results - Business Wire
- 2 days ago - Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects - Business Wire
- 6 days ago - Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon - Business Wire
- 10 days ago - STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon - Business Wire
- 13 days ago - Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon - Business Wire
- 13 days ago - Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction - Business Wire
- 14 days ago - Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders - Business Wire